The intent of the Clinical Trial Award is to provide for the rapid execution of novel patient-oriented research in a Phase I, Phase I/II, or Phase II clinical trial that has the potential to significantly impact the treatment, diagnosis, detection, or prevention of prostate cancer. Proposals should focus on new interventions (e.g., drugs, biologics, and devices.)
This award is intended to support both new and established scientists across a broad spectrum of disciplines. The FY05 Clinical Trial Award is open to all eligible applicants with clinical trials relevant to prostate cancer treatment, diagnosis, detection, or prevention. In addition, as stated in the FY04 Clinical Trial Development Award Program Announcement, recipients of the FY04 Clinical Trial Development Award are required to compete for the FY05 Clinical Trial Award. All applicants must submit proposals, clinical protocols, and other supporting clinical documents.
Please note that funding for the Clinical Trial Award mechanism is subject to availability and passage of appropriate Congressional language. However, based on this Command's knowledge of the appropriation history for these programs, it is believed that Congress will provide the funds for this project.
Approximately $5M is anticipated to be available for this award mechanism. It is anticipated that this award mechanism will fund approximately five awards for up to $750,000 each in direct costs over a 3-year period of performance, plus indirect costs as appropriate. Direct costs can cover salary, expenses including research supplies, and travel to scientific meetings. The amount for travel to scientific meetings may not exceed $1,800 per year per investigator. Applicants should also budget for travel to a pre-award meeting and protocol workshop at Fort Detrick, Maryland and a reverse site visit in the Baltimore-Washington, DC area during the period of performance.
Applicants should clearly specify in the proposal which type of Clinical Trial Award is being requested (i.e., Phase I, Phase I/II, or Phase II).
All applicants must provide evidence of sufficient institutional support and commitment for the proposed studies, such as the provision of access to adequate laboratory facilities and equipment. Consideration of cost sharing with other funding sources and multi-institutional/multidisciplinary research collaborations is encouraged. The nature of this award mechanism does not allow for renewal of grants or supplementation of existing grants with DOD funds.
Electronic submission is required. No paper copy submissions will be accepted. Please see the Full Text of Program Announcement for details.
POC for this action is Joseph Little, Contracting/Grants Officer, 301-619-2546, Fax 301-619-6662, Email Joseph.Little@det.amedd.army.mil
Who can apply:
Eligible functional categories:
Military Medical Research and Development
eReceipt Online Proposal Submission Congressionally Directed Medical Research Programs
If you have problems accessing the full announcement, please contact:
US Army Medical Research Acquisition Activity, ATTN: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014